Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Oncology
- Publicado em
- 11 ago 2025
- Citações
- 13
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, Taito Esaki, David Páez Lopez-Bravo, Julien Taieb, Michalis Karamouzis, Erika Ruiz-Garcia, Tae Won Kim, Yasutoshi Kuboki et al.
Descritores MeSH
- Colorectal Neoplasms
- Mutation
- Pyrimidines
- Quality of Life
- Proto-Oncogene Proteins p21(ras)
- Antineoplastic Combined Chemotherapy Protocols
- Panitumumab
- Female
- Drug Combinations
- Adult
Veja também
Estudos relacionados
- Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
- Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis
- Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis
- Comparação Indireta Ajustada à Correspondência de Sotorasib Plus Panitumumab Versus Trifluridina/Tipiracil Plus Bevacizumab em Câncer Colorectal Metastático Chemorefractory